Literature DB >> 7708723

Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens.

A Y Lee1, S K Chung, S S Chung.   

Abstract

Aldose reductase (AR) has been implicated in the etiology of diabetic cataract, as well as in other complications. However, the role of AR in these complications remains controversial because the strongest supporting evidence is drawn from the use of AR inhibitors for which specificity in vivo cannot be ascertained. To settle this issue we developed transgenic mice that overexpress AR in their lens epithelial cells and found that they become susceptible to the development of diabetic and galactose cataracts. When the sorbitol dehydrogenase-deficient mutation is also present in these transgenic mice, greater accumulation of sorbitol and further acceleration of diabetic cataract develop. These genetic studies demonstrated convincingly that accumulation of polyols from the reduction of hexose by AR leads to the formation of sugar cataracts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7708723      PMCID: PMC42302          DOI: 10.1073/pnas.92.7.2780

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  [The mechanism of the formation of seminal fructose and fetal fructose].

Authors:  H G HERS
Journal:  Biochim Biophys Acta       Date:  1960-01-01

2.  The absence of cataracts in mice with congenital hyperglycemia.

Authors:  S D Varma; J H Kinoshita
Journal:  Exp Eye Res       Date:  1974-12       Impact factor: 3.467

Review 3.  Mechanisms initiating cataract formation. Proctor Lecture.

Authors:  J H Kinoshita
Journal:  Invest Ophthalmol       Date:  1974-10

4.  Cataracts in galactosemia. The Jonas S. Friedenwald Memorial Lecture.

Authors:  J H Kinoshita
Journal:  Invest Ophthalmol       Date:  1965-10

5.  Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.

Authors:  A Beyer-Mears; L Ku; M P Cohen
Journal:  Diabetes       Date:  1984-06       Impact factor: 9.461

6.  N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.

Authors:  K Sestanj; F Bellini; S Fung; N Abraham; A Treasurywala; L Humber; N Simard-Duquesne; D Dvornik
Journal:  J Med Chem       Date:  1984-03       Impact factor: 7.446

7.  Effects of a new aldose reductase inhibitor on various tissues in vitro.

Authors:  H Terashima; K Hama; R Yamamoto; M Tsuboshima; R Kikkawa; I Hatanaka; Y Shigeta
Journal:  J Pharmacol Exp Ther       Date:  1984-04       Impact factor: 4.030

8.  Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.

Authors:  D Finegold; S A Lattimer; S Nolle; M Bernstein; D A Greene
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461

9.  Sorbitol dehydrogenase genetics in the mouse: a 'null' mutant in a 'European' C57BL strain.

Authors:  R S Holmes; J A Duley; J Hilgers
Journal:  Anim Blood Groups Biochem Genet       Date:  1982

10.  Purification and characterization of human-brain aldose reductase.

Authors:  B Wermuth; H Bürgisser; K Bohren; J P von Wartburg
Journal:  Eur J Biochem       Date:  1982-10
View more
  66 in total

Review 1.  Pathogenesis of diabetic nephropathy.

Authors:  Claudia van Dijk; Tomas Berl
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  Lens Biology and Biochemistry.

Authors:  J Fielding Hejtmancik; S Amer Riazuddin; Rebecca McGreal; Wei Liu; Ales Cvekl; Alan Shiels
Journal:  Prog Mol Biol Transl Sci       Date:  2015-06-04       Impact factor: 3.622

3.  Topical KINOSTAT™ ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus.

Authors:  Peter F Kador; Terah R Webb; Dineli Bras; Kerry Ketring; Milton Wyman
Journal:  Vet Ophthalmol       Date:  2010-11       Impact factor: 1.644

Review 4.  Oxidative stress and diabetic complications.

Authors:  Ferdinando Giacco; Michael Brownlee
Journal:  Circ Res       Date:  2010-10-29       Impact factor: 17.367

Review 5.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

6.  Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels.

Authors:  Linlin Zhong; Ziwen Liu; Ruilan Yan; Stephen Johnson; Yupei Zhao; Xiubin Fang; Deliang Cao
Journal:  Biochem Biophys Res Commun       Date:  2009-06-27       Impact factor: 3.575

7.  Differential control of murine aldose reductase and fibroblast growth factor (FGF)-regulated-1 gene expression in NIH 3T3 cells by FGF-1 treatment and hyperosmotic stress.

Authors:  D K Hsu; Y Guo; K A Peifley; J A Winkles
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

8.  Aldo-keto reductases in the eye.

Authors:  Shun Ping Huang; Suryanarayana Palla; Philip Ruzycki; Ross Arjun Varma; Theresa Harter; G Bhanuprakesh Reddy; J Mark Petrash
Journal:  J Ophthalmol       Date:  2010-06-13       Impact factor: 1.909

Review 9.  The eye as a window to inborn errors of metabolism.

Authors:  B T Poll-The; L J Maillette de Buy Wenniger-Prick; P G Barth; M Duran
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Exclusion of NFAT5 from mitotic chromatin resets its nucleo-cytoplasmic distribution in interphase.

Authors:  Anaïs Estrada-Gelonch; Jose Aramburu; Cristina López-Rodríguez
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.